Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
| ▸ | SPTLC2 | O15270 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1938358 | 1.00 | LMNA (0.49) | LMNACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL7932432 | 1.00 | LMNA (0.49) | LMNACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2799214 | 0.80 | TLR2 (0.53) | LMNACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1937652 | 0.80 | TLR2 (0.53) | LMNACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL7921209 | 0.80 | TLR2 (0.53) | LMNACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1935651 | 0.76 | LMNA (0.46) | LMNACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1936843 | 0.74 | LMNA (0.46) | LMNACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2797622 | 0.74 | LMNA (0.46) | LMNACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL7934320 | 0.74 | LMNA (0.46) | LMNACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL27460649 | 0.70 | LMNA (0.47) | LMNACYP3A4CYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293770-B2 | Pyrrolidine derivatives as NK-3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100168088-A1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168088-A1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | OPRK1, OPRL1, OPRD1 | LMNA 4783/4885CYP3A4 2181/4885CYP2C9 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.